US Real-World Management of EGFR-Mutated Advanced NSCLC: Prescribing and Attrition Data from First-To-Second-Line Treatment

被引：5
|
作者：
Reckamp, K. [1 ]
Nieva, J. [2 ]
Taylor, A. [3 ]
Thakrar, B. [3 ]
Wong, J. [4 ]
Potter, D. [3 ]
Bakker, N. [5 ]
Rubinstein, W. [6 ]
Sun, P. [7 ]
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] Univ Southern Calif, Norris Canc Ctr, Los Angeles, CA USA
[3] Astrazeneca, Global Med Affairs, Oncol Business Unit, Global Epidemiol, Cambridge, England
[4] Astrazeneca, Med Evidence & Observat Res Ctr, Global Med Affairs, Gaithersburg, MD USA
[5] Astrazeneca, Oncol Business Unit, Med, Cambridge, England
[6] Cancerlinq Llc, Amer Soc Clin Oncol, Alexandria, VA USA
[7] Astrazeneca, Med Evidence & Observat Res Ctr, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
EGFRm; NSCLC; attrition;
D O I：
10.1016/j.jtho.2019.08.820
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-105
引用
收藏
页码：S402 / S402
页数：1
相关论文
共 50 条
  • [31] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Ying Cheng
    Yong He
    Wei Li
    He-long Zhang
    Qing Zhou
    Buhai Wang
    Chunling Liu
    Andrew Walding
    Matilde Saggese
    Xiangning Huang
    Minhao Fan
    Jia Wang
    Suresh S. Ramalingam
    Targeted Oncology, 2021, 16 : 165 - 176
  • [32] A bayesian network comparison of different agents or regimens as first-line treatment for advanced EGFR-mutated NSCLC.
    Liang, Wenhua
    He, Qihua
    Zhang, Jianrong
    Jiang, Long
    Zhou, Caicun
    He, Jianxing
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
    Bin-Chi Liao
    Chia-Chi Lin
    James Chih-Hsin Yang
    Drugs, 2013, 73 : 357 - 369
  • [34] First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
    Liao, Bin-Chi
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    DRUGS, 2013, 73 (04) : 357 - 369
  • [35] Real-World Evaluation of Tolerability in Older Adult Patients (≥75 years old) with EGFR-mutated NSCLC
    Jiang, S.
    Hurry, M.
    Hueniken, K.
    Labbe, C.
    Brown, M. C.
    Eng, L.
    Naik, H.
    Liang, M.
    Patel, D.
    Bradbury, P.
    Leighl, N.
    Shepherd, F.
    Xu, W.
    Liu, G.
    Walton, R.
    O'Kane, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S476 - S477
  • [36] Real-world outcomes of second-line osimertinib for advanced NSCLC patients with EGFR mutation in China
    Ji, W.
    Li, X.
    Cang, S.
    Xiang, Y.
    Li, X.
    Zhang, J.
    Tan, J.
    Wang, Q.
    Jiang, D.
    Zhang, H.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1067 - S1067
  • [37] Real-world EGFR testing patterns among US patients with advanced NSCLC
    Vanderpoel, Julie
    Pericone, Chris
    He, Jinghua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [38] First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
    Ji, W.
    Jiang, D.
    Zhang, J.
    Zhang, H.
    Wang, Q.
    Cang, S.
    Li, X.
    Tan, J.
    Xiang, Y.
    Li, X.
    Liu, A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1693
  • [39] High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study
    Chen, Haiyang
    Yang, Sen
    Wang, Lili
    Wu, Yingxi
    Wu, Yufeng
    Ma, Shuxiang
    He, Zhen
    Zhang, Cuicui
    Liu, Yang
    Tang, Haoran
    Dong, Hang
    Wang, Qiming
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 65 - 75
  • [40] Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US
    Li, Y.
    Appius, A.
    Pattipaka, T.
    Feyereislova, A.
    Cassidy, A.
    Ganti, A. K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2216 - S2216
12345